A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Inclusion Criteria: * Adults ≥18 to ≤ 70 years of age at the time of the Screening Visit * History of type 2 diabetes * Body mass index (BMI) ≥18 to ≤45 kg/m2 at the Screening Visit * Use of approved methods of contraception * Ability to provide written informed consent Exclusion Criteria: * Type 1 diabetes * Significant acute diabetic proliferative retinopathy or severe neuropathy * Systolic blood pressure \>160 mm Hg and/or diastolic blood pressure \>100 mm Hg at screening * Pregnant or lactating women * Participation in an investigational study within 30 days prior to randomization * History of any major surgery within 6 months prior to Screening * History of any serious adverse reaction or hypersensitivity to any of the product components. * History of renal disease or significantly abnormal kidney function tests at Screening * History of hepatic disease or significantly abnormal liver function tests * History of any active infection within 30 days prior to Randomization * Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results * Concurrent conditions that could interfere with safety and/or tolerability measurements per the investigator * Donation or loss of \>500 mL of blood or blood product within 56 days of Randomization